Prolonged allograft survival by the inhibition of costimulatory CD2 signals but not by modulation of CD48 (CD2 ligand) in the rat

Transplant International : Official Journal of the European Society for Organ Transplantation
B SidoT J Dengler

Abstract

The CD2 receptor is an important costimulatory molecule in T cell activation. Its ligand CD48 in rodents is supposed to be a homologue of human CD58, because of its similarities in structure and distribution. We evaluated the immunosuppressive activity of CD2/CD48-directed therapy in vitro and in vivo for the efficacy in prolonging rat heart allograft survival in a high responder transplant model. CD2-directed monoclonal antibody (mAb) therapy significantly prolonged median survival time to 45 days (P < 0.001). Suppression was mediated by down-modulation of CD2 below 20% on lymph node cells without considerable cell depletion. In contrast, CD48 mAb could not prolong graft survival. Rejection occurred in the presence of complete CD48 modulation and, therefore, despite disruption of the CD2-CD48 interaction. CD48 mAb failed to inhibit lymphocyte activation via a mitogenic pair of CD2 mAbs and inhibited mixed lymphocyte reaction (MLR) only by an unspecific mechanism. In conclusion, our results suggest a negative regulatory signal transduction by inhibitory CD2 mAbs and argue against a pivotal role of mere disruption of the CD2-CD48 interaction in CD2-mediated immunosuppression.

References

Nov 1, 1992·The Journal of Experimental Medicine·K KatoH Yagita
Jun 1, 1988·The Journal of Experimental Medicine·S J ClarkA F Williams
May 1, 1994·International Immunology·K D ChavinJ S Bromberg
Jan 27, 1995·Transplantation·S TodoT E Starzl
Jan 1, 1994·The Journal of Experimental Medicine·L QinJ S Bromberg

❮ Previous
Next ❯

Citations

Sep 9, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Stephen P Cobbold
Jul 6, 2004·European Journal of Biochemistry·Liu JiningSeetharama D S Jois
Nov 5, 2008·Transplant International : Official Journal of the European Society for Organ Transplantation·Thomas HaudebourgBernard Vanhove
Jun 26, 2021·Frontiers in Immunology·Yalu ZhangQuan Liao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.